Clinical Trial Update: A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating BB102 for hepatocellular carcinoma is planned but not yet recruiting, sponsored by Broadenbio Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BB102

Snippet

Sponsor: Broadenbio Ltd., Co. | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: NOT_YET_RECRUITING